Antibody-drug conjugate that exhibits synergistic cytotoxicity with an endosome-disruptive peptide

Keyphrases

• Endosome 100%
• Antibody-drug Conjugate 100%
• Synergistic Cytotoxicity 100%
• Cytotoxin 66%
• IC50 50%
• Small Molecules 33%
• Disulfide 33%
• Cell Surface Receptor 16%
• Breast Cancer Cells 16%
• Cytotoxicity 16%
• Cancer Therapeutics 16%
• Cholesterol 16%
• Human Epidermal Growth Factor Receptor 2 (HER2) 16%
• Subnanomolar 16%
• Efflux 16%
• Endocytosis 16%
• Conjugation 16%
• Antibody Conjugates 16%
• Targeting Antibodies 16%
• Herceptin 16%
• Fluorophore 16%
• Endosomal Escape 16%
• Endolysosomal System 16%
• Lysine Residue 16%
• Low Toxicity 16%
• Receptor-mediated Endocytosis 16%
• SKBR3 16%
• Trastuzumab 16%
• Low Cytotoxicity 16%
• Membrane Permeable 16%
• HER2-targeted Therapy 16%
• Reduced Glutathione 16%
• Tubulin Binding 16%
• Cytotoxic Potency 16%
• Methyl Ethers 16%

Immunology and Microbiology

• Endosome 100%
• Cytotoxicity 100%
• Antibody Drug Conjugate 100%
• IC50 50%
• Endocytosis 33%
• Trastuzumab 33%
• Immunology 33%
• Cell Surface 16%
• Cancer Cell 16%
• Antibody Conjugate 16%
• Conjugate 16%